{"title":"New treatments for migraine … and other research","authors":"Tom Nolan","doi":"10.1136/bmj.q1967","DOIUrl":null,"url":null,"abstract":"Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate cyclase-activating polypeptide (PACAP). The phase 2 trial recruited adults with migraine with an average of 16.7 migraine days per month and for whom two to four preventive treatments had failed. Those given a single infusion of Lu AG09222 750 mg had an average of 6.2 fewer migraine days over the following month, compared with 4.2 fewer in the placebo group (a between-group difference of two days (95% confidence interval −3.8 to −0.3)). With this positive phase 2 result, it’s time for Lu AG09222 to PACAP its bags and go to phase 3. N Engl J Med doi:10.1056/NEJMoa2314577 Infectious disease specialists like to keep fit by lifting heavy parcels of …","PeriodicalId":22388,"journal":{"name":"The BMJ","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The BMJ","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmj.q1967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate cyclase-activating polypeptide (PACAP). The phase 2 trial recruited adults with migraine with an average of 16.7 migraine days per month and for whom two to four preventive treatments had failed. Those given a single infusion of Lu AG09222 750 mg had an average of 6.2 fewer migraine days over the following month, compared with 4.2 fewer in the placebo group (a between-group difference of two days (95% confidence interval −3.8 to −0.3)). With this positive phase 2 result, it’s time for Lu AG09222 to PACAP its bags and go to phase 3. N Engl J Med doi:10.1056/NEJMoa2314577 Infectious disease specialists like to keep fit by lifting heavy parcels of …
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
